MedTech Dive, Jan 13, 2025: MedTech outlines 5 key issues as MDUFA negotiations restart, including FDA staffing, device safety and effectiveness, and transparency. The article highlights growing concern from NCHR’s Diana Zuckerman and other patient and consumer groups that safety and effectiveness may receive less attention than faster device approvals.
Read More »News That Quotes Us & Our Work
We are often quoted in major newspapers and magazines, and on well-respected TV shows, radio programs, and websites where we share our opinion on issues that matter to you and your health. Stay up to date on health news and our take on it by reading the articles in this section.
These are the treatments dominating the business of living longer
Washington Post, January 12, 2026: NCHR is quoted in article about supporters and skeptics about longevity research and resulting products being sold, promoted, and supported by RFK’s HHS but not necessarily approved by FDA.
Read More »Top drug regulator Richard Pazdur set to leave the FDA
STAT reports Pazdur sudden FDA retirement as CDER head as we agree with industry in questioning if FDA can function as a scientific and public health agency when it can’t keep dedicated staff amid controversial decisions on vaccines and other medical products.
Read More »What the shutdown’s end means for FDA
Politico, November 14, 2025: Politico quotes experts’ questions regarding FDA Commissioner Makary’s plausible mechanism pathway described in NEJM. NCHR Diana Zuckerman doubts insurance would pay for such expensive drugs based on “plausible mechanism” rather than evidence that they are safe and effective.
Read More »STAT: In an unconventional process, FDA reverses a decades-old warning for hormone therapy
STAT News, Nov. 11, 2025: STAT News describes the diversity of views on the decision to remove black
box warnings for menopausal hormone therapy, but the HHS announcement and
description of hormone therapy benefits was more PR than science, says NCHR Dr.
Diana Zuckerman